Investment Thesis
OS Therapies faces imminent insolvency with negative stockholders' equity (-$6.1M), catastrophic liquidity crisis (0.03x current ratio), and only $270K cash against $28.8M net losses. At current burn rates, the company has less than 2 weeks of cash runway and lacks capacity to fund operations without immediate external capital. The combination of pre-revenue status, balance sheet insolvency, and near-zero liquid reserves creates extreme going-concern risk.
Strengths
- Pre-revenue status is normal for early-stage biotech/pharmaceutical companies
- Recent insider activity (8 Form 4 filings) may indicate some management engagement
- Operating in pharmaceutical sector has potential long-term value if pipeline succeeds
Risks
- Negative stockholders' equity indicates technical insolvency on balance sheet
- Critical liquidity crisis with 0.03x current ratio - insufficient to cover liabilities
- Only $269.8K cash with $28.8M annual net losses - less than 2 weeks operational runway
- No revenue generation; 100% dependent on capital raises or asset liquidation
- Severe risk of dilutive financing required for survival
- Going concern risk - company may be unable to fund normal operations
- Liabilities ($11.9M) exceed assets ($6.8M) by $5.1M
Key Metrics to Watch
- Cash balance and monthly burn rate
- Ability to secure capital injection or financing
- Operating expenses and cost containment progress
- Clinical trial milestones and regulatory pathway updates
- Share dilution from equity financings
- Total liabilities and accounts payable aging
- Timeline to revenue-generating assets or cash-generating events
Financial Metrics
Revenue
N/A
Net Income
-28.8M
EPS (Diluted)
$-0.98
Free Cash Flow
-14.7M
Total Assets
6.8M
Cash
269.8K
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-420.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.03x
Quick Ratio
0.03x
Debt/Equity
N/A
Debt/Assets
173.5%
Interest Coverage
-34.64x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-13T20:39:22.662587 |
Data as of: 2025-12-31 |
Powered by Claude AI